

National Web-Based Teleconference on Health IT Preventing Errors and Promoting Safety Through Better Medication Management

February 16, 2011

Moderator:

Angela Lavanderos

Agency for Healthcare Research and Quality

Presenters:

Donna Horn

Andrea Wessel

Chris Lehmann

Judy Smetzer

**AHRQ National Resource Center
for Health Information Technology**



Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov



Preventing Errors and Promoting Safety through Better Medication Management

Introduction **Donna Horn RPh, DPh**

I do not have any relevant financial relationships with any commercial interests to disclose.

Definitions

- Medication errors
 - Wrong patient, drug, dose, frequency, route, dosage form, administration directions
 - Presence of contraindication
 - Inappropriate duplicative therapy
 - Important drug-drug interaction
- Adverse drug events (ADEs)
 - Injuries from drug therapy
- Preventable adverse drug events (PADEs)
 - At least a quarter of ADEs are preventable¹⁻³
 - Among the most common causes of harm during care



Scope and Significance

Are PADEs really that bad...?



Scope and Significance

Inpatient

- Prescription errors (PADEs)
 - 3.7 to 84.1 per 1,000 admissions³⁻⁷
- Preparation/dispensing errors (PADEs)
 - 1.1 to 1.6 per 1,000 admissions^{3,7}
- Drug administration errors (PADEs)
 - 2.1 to 17.9 per 1,000 admissions^{3,7}
- 450,000 patients experience PADE each year^{3,8}
 - 4% (1.4-15.4%) of all hospital admissions⁹⁻¹⁵



Scope and Significance

Outpatient

- Community pharmacies
 - 1.7% to 24% dispensing error rate¹⁶⁻¹⁹
- Even with lowest error rate (1.7%)
 - 4 errors per 250 prescriptions⁵
 - 60 million PADEs annually²⁰
- 5% ambulatory patients experience PADEs¹⁵
 - Dosing errors highest clinical significance
- \$121.5 billion for hospital admissions²¹
 - 70% of total costs of drug-related problems



Scope and Significance

Other ambulatory settings

- Outpatient pediatric clinics
 - 15% wrong dose prescribing errors for 22 common drugs²²
- Ambulatory clinics
 - 21% prescribing errors²³
 - 17% samples dispensed refer to absent packaging information²⁴
- Hemodialysis unit
 - 97.7% patients subject to prescribing errors²⁵



Patients at Higher Risk for PADEs

- Patients on multiple medications
- Patients with low health literacy
- Elderly patients
- Patients with renal or liver impairment
- Pediatrics



High-Alert Medications (Ambulatory)

Drug Class/Category

- Antiretroviral agents
- Chemotherapy, oral
- Hypoglycemic agents, oral
- Immunosuppressant agents
- Insulin
- Opioids, all formulations
- Pregnancy category X drugs
- Pediatric liquid medications that require measurement

Individual Drugs

- carbamazepine
- chloral hydrate liquid
 - sedation of children
- heparin
- methotrexate
 - non-oncologic use
- midazolam liquid
 - sedation of children
- propylthiouracil
- warfarin



Error-Reduction Strategies

- Forcing functions
- Barriers and fail-safes
- Automation and computerization
- Redundancies
- Recovery
- Standardization and protocols
- Performance shaping factors
(e.g., checklists, reminders)
- Rules and policies
- Education
- Information
- Make no mistake

Improve system
reliability

Improve human
reliability



References

1. Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. *New Engl J Med.* 1991;324(6):370-376.
2. Bates DW, Spell N, Cullen DJ, et al. The cost of adverse drug events in hospitalized patients. *JAMA.* 1997;277(4):307-311.
3. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. *JAMA.* 1995;274(1):29-34.
4. Kohn LT, Corrigan JM, Donaldson MS, eds. *To err is human: building a safer health system.* Washington, DC: The National Academies Press; 2000.
5. Aspden P, Wolcott JA, Bootman JL, Cronenwett, LR, eds. *Preventing Medication Errors: Quality Chasm Series.* Washington, DC: The National Academies Press; 2007.
6. Hardmeier B, Braunschweig S, 2004 Cavallaro M, Roos M, et al. Adverse drug events causes by medication errors in medical inpatients. *Swiss Medical Weekly.* 134(45-46):664-70
7. Nebeker JR, Hoffman JM, Weir CR, Bennett CL et al. High rates of adverse drug events in a highly computerized hospital. *Arch Intern Med.* 2005;165(10):1111-1116.
8. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. *JAMA.* 1997;277(4):301-306.
9. Porter J, Jick H. Drug-related deaths among medical inpatients. *JAMA.* 1977;237(9):879-881.
10. Phillips J, Beam S, Brinker A, et al. Retrospective analysis of mortalities associated with medication errors. *Am J Health Syst Pharm.* 2001;58(22):1835-1841.
11. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. *JAMA.* 1998;279(15):1200-1205.
12. Howard R, Avery A, Bissell P. Causes of preventable drug-related hospital admissions: a qualitative study. *Qual Saf Health Care.* 2008;17(2):109-116.



References (cont'd)

13. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. *Br J Clin Pharmacol*. 2007;63(2):136-147.
14. Budnitz DS, Pollock DA, Weidenbach KN, et al. National surveillance of emergency department visits for outpatient adverse drug events. *JAMA*. 2006;296(15):1858-1866.
15. Ghandi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. *New Engl J Med*. 2003;348(16):1556-1564.
16. Buchanan TL, Barker KN, Gibson JT, et al. Illumination and errors in dispensing. *Am J Hosp Pharm*. 1991;48(10):2137-2145.
17. Flynn EA, Barker KN, Berger BA, et al. Dispensing errors and counseling quality in 100 pharmacies. *J of Amer Pharm Assoc*. 2009;49(2):171-80.
18. Allan EL, Barker KN, Malloy MJ, et al. Dispensing errors and counseling in community practice. *Am Pharm*. 1995;NS35(12):25-33.
19. Flynn EA, Barker KN, Carnahan BJ. National observational study of prescription dispensing accuracy and safety in 50 pharmacies. *J Am Pharm Assoc*. 2003;43(2):191-200.
20. Szeinback S, Seoane-Vazquez E, Parekh A, et al. Dispensing errors in community pharmacy: perceived influence of sociotechnical factors. *Int J Qual Health Care*. 2007;19(4):203-209.
21. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. *J Am Pharm Assoc*. 2001;41(2):192-199.
22. McPhillips HA, Stille CJ, Smith D, Hecht J, et al. Potential medication dosing errors in outpatient pediatrics. *J of Peds*. 2005;147(6):761-767.
23. Shaughnessy AF, Nickel RO. Prescription-writing patterns and errors in a family medicine residency program. *J Family Practice*. 1989;29(3):290-295.
24. Dill JL, Generali JA. Medication sample labeling practices. *Am J of Health Syst Pharm*. 2000; 57(22):2087-2090.
25. Manley HJ, Drayer DK, Muther RS. Medication-related problem type and appearance rate in ambulatory hemodialysis patients. *BMC Nephrology*. 2003;22:4-10.





Preventing Errors and Promoting Safety through Better Medication Management: The PPRNet Experience

Andrea Wessell, PharmD, BCPS, CDE
PPRNet, Medical University of South Carolina
Charleston, SC

I do not have any relevant financial relationships with any commercial interests to disclose.

AHRQ Grant Number 1R18HS017037



Acknowledgements



- PPRNet Research Team
 - Steven Ornstein, MD
 - Ruth Jenkins, PhD
 - Paul Nietert, PhD
 - Lynne Nemeth, PhD, RN
 - Cara Litvin, MD, MS
- PPRNet practices
- Agency for Healthcare Research and Quality
Ambulatory Safety and Quality Program: Improving
Quality through Clinician Use of Health IT

Learning Objectives

1. Describe the importance of health IT in preventing patient safety errors.
- 2. Examine successful error prevention strategies from real-world practice.**




MS-TRIP: Medication Safety in Primary Care Practice – Translating Research into Practice

- 3-year demonstration project in 20 PPRNet practices
- Goals:
 1. Develop a set of medication safety indicators relevant to primary care
 2. Incorporate indicators into PPRNet quarterly reports
 3. Assess impact of PPRNet-TRIP quality improvement model on indicators



Background: PPRNet

- Nationwide primary care practice-based research network among users of a common electronic health record (EHR)
- Medication safety decision support features within EHR
 - Allergy, drug-drug and drug-disease and interaction alerts
 - Dosing calculators
 - Monitoring prompts





MS-TRIP Practice Characteristics



		Practice count
Geographic location	South	9
	Midwest	5
	West	4
	Northeast	2
Number of clinicians	1 or 2	11
	3 or 4	7
	10 or greater	2
Practice type	Physician-owned	14
	Hospital-owned	3
	Other	3



MS-TRIP Intervention



Reports

- Quarterly
- Performance over time with benchmarks
- Lists of de-identified patients with potential errors

Site Visits

Network Meetings





MS-TRIP Intervention



Reports

- Quarterly
- Performance over time with benchmarks
- Lists of de-identified patients with potential errors

Site Visits

- Annually
- On site meeting with practice staff and clinicians
- Academic detailing
- Performance review
- Improvement planning
- QI implementation assistance

Network Meetings





MS-TRIP Intervention



Reports

- Quarterly
- Performance over time with benchmarks
- Lists of de-identified patients with potential errors

Site Visits

- Annually
- On site meeting with practice staff and clinicians
- Academic detailing
- Performance review
- Improvement planning
- QI implementation assistance

Network Meetings

- Annually
- “Best practice” dissemination
- Small group workshops on overcoming challenges in implementation






MS-TRIP Indicator Set



- Avoiding potentially inappropriate therapy (3)
- Avoiding potentially inappropriate dosages (4)
- Avoiding potential drug-drug interactions (8)
- Avoiding potential drug-disease interactions (9)
- Monitoring of potential adverse events (20)

Median Summary Performance in Medication Safety Measures Over Time





Medication Error Prevention Strategies





Practice Strategies



- Assure the accuracy of each patient's recorded medication list
- Integrate EHR decision support features into routine practice
- Implement a practice refill and monitoring protocol
- Utilize medication safety practice performance reports





Accurate Medication Lists



- Document all medications prescribed by practice providers
- Implement a process for patient review of EHR medication list
 - Inquire and evaluate use of nonprescription therapy and medications from outside providers
- Distribute printed medication list at the end of each visit





EHR Decision Support



- Review alerts and adjust prescribing as necessary
- Calculate doses based on renal function
- Apply medication monitoring protocols

Current | Ineffective | Historical | Rx Fill History | Eligibility

Date	Name	Size	Take	Freq	Dur	Amt	Refill	Prov	Oper	Sign	Co-Sign Prv	Co-Sign Op	Co-Sign
11/10/09	ASPIRIN EC	81MG	1 TAB	daily		30	11	ABC					
05/20/10	CHLORTHALIDONE	12.5mg	1 TAB	daily		30	11	Outside					

Prescription: Johnson, Bill <New>

Rx Template C of PEPCID40 | Lookup | by Template C C by Indicator
Rx Template N of PEPCID 40MG QHS X 30D

Date: 08/17/10 Medication: PEPCID Size: 40MG Take: 1 TAB
Freq: at bedtime Dur: 30 Amount: 11 Refills: 11 Route: ORAL

Print: Print locally immediately | Prov: ABC pmsi pmsi Outside

Indication: [Lookup] Formula: [Lookup]
Note: Reduce dose in elderly and low CrCl (20 mg/d) [Details] [Alternative]

Extended Sig: [Dropdown] Code: [Lookup] Create Sig Templ

Use Extended Limit Refill Drug Interaction Ch New Rx Templ
 Use Extended Sig Substitution C Allergy Che
 Use Patient Instructi Update Progress I Change Pharma OTC

Wholesale price per unit Total price Insurance Tol (no p
Generic price per unit Total price

OK Cancel Alternative... Dose Advisor Help

Dose Advisor for: Johnson, Bill |PEPCID, ORAL|

Dose Type: Maintenance Dose Serum Creatinine: 1.4 mg/dL on 8/17/2010
Indication: Gastroesophageal Reflux Disease
Weight: 68.2 kg on 11/24/2009 Estimated Creatinine Clearance: 45 ml/min
Height: 165 cm on 11/24/2009 Update Previously Recorded Creatinine Clearance: ml/min

Liquid

Size: 20 MG Take: 1 tablet Freq: every other day Dur: Extended Sig: [Dropdown]

OK Cancel Calculate Help



Refill and Monitoring Protocols



- Educate staff on refill protocol and use of decision support
 - Schedule refills according to monitoring requirements
 - Limit refills if overdue for follow-up
- Empower staff to review monitoring prompts and implement standing orders

Health Maintenance Summary: Johnson, Bill

	Recommend F	Due (seq.#)	08/17/201	11/24/200	11/22/200	10/3
Alcohol	65-74 YEAR OLD	11/25/2011		X		X
Aspirin therapy	Multiple					X
BP	Multiple	05/24/2010		X		
Cholesterol	65-74 YEAR OLD	11/24/2014		X		
Colonoscopy	65-74 YEAR OLD	11/10/2009		O		
Creatinine	ARB	08/17/2011	X			
Depression	65-74 YEAR OLD	11/10/2009				
Diet Counseling	DIABETES MELL	11/10/2009				
Exercise Counsel	DIABETES MELL	11/24/2010		X		
Eye exam	DIABETES MELL	11/24/2010		X		
F.O.B.	65-74 YEAR OLD			N		
Flex Sig	65-74 YEAR OLD			N		
Foot Exam	DIABETES MELL	11/24/2010		X		
Glucose,Fasting	65-74 YEAR OLD			X		
HDL Cholesterol	Multiple	05/24/2010		X		
Hearing	65-74 YEAR OLD	11/24/2014		X		
Height	65-74 YEAR OLD	11/24/2011		X		
Hemoglobin A1C	DIABETES MELL	05/24/2010		X		
Influenza vaccine	Multiple	11/10/2009				
LDL Cholesterol	Multiple	11/24/2010		X		
Microalbumin, Ur	DIABETES MELL	11/10/2009				
Pneumococcal poly	Multiple	01/16/2002				
Potassium	ARB	08/17/2011	X			
Smoking Counseling	Multiple	11/24/2010		X		X
Td	65-74 YEAR OLD	11/10/2009				
Triglycerides	Multiple	11/24/2010		X		
Visual Acuity	65-74 YEAR OLD	11/24/2011		X		
Weight	65-74 YEAR OLD	11/25/2010		X	X	X
Zoster	65-74 YEAR OLD	01/16/2002		R		





Reports



- Utilize reports to evaluate performance and guide improvement plans
- Design and execute case management for patients with potential error
 - Message providers within EHR
 - Highlight potential error on EHR medication list
 - Contact patients with adjustments or monitoring instructions

Measure Description/Criterion	Description of Eligible Patients	Number of Eligible Patients	Percent Meeting Criterion	Number Not Meeting Criterion	PPRNet Median	PPRNet Benchmark
Avoiding Potentially Inappropriate Dosages:						
Allopurinol: Greater than 200 mg/day; Greater than 100 mg/day	Pts with an active rx* and GFR^ 20-60 ml/min or GFR <= 20 ml/min	23	48%	12	71%	100%
Benzodiazepines: Greater than daily dose for alprazolam 2mg, lorazepam 3mg, oxazepam 60mg, temazepam 15mg, and triazolam 0.25mg	Pts >= 65 years and active rx	87	94%	5	95%	99%
Digoxin: Greater than 0.125 mg/day	Pts >= 65 yrs with Dx of Heart Failure and active	3	100%	0	95%	100%
H-2 blocker: Greater than daily dose for cimetidine 1200mg, famotidine 20mg, nizatidine 150mg, ranitidine 150mg	Pts with GFR < 50 ml/min and an active rx	14	57%	6	50%	77%



Preventing Errors and Promoting Safety through Better Medication Management: The PPRNet Experience

- In the context of a quality improvement intervention, PPRNet practices implemented a consistent set of safety strategies in:
 - Practice redesign
 - Team involvement
 - Patient activation
 - Enhanced use of health IT tools





Thank You!



The Road to Safer Patient Care: Leveraging IT

Christoph U. Lehmann, MD

Director, Clinical Information Technology

Johns Hopkins Children's Medical and Surgical Center

clehmann@jhmi.edu

I do not have any relevant financial relationships with any commercial interests to disclose.



Approach to Errors

- Person approach
 - based on assigning blame
 - focuses on individuals
 - punitive in nature
- Systems approach
 - based on preventing recurrence of errors
 - focuses on system vulnerabilities
 - constructive and inclusive in nature

System Failures

- Human fallibility is only part of the problem
- Failures at the system level
 - in disseminating pharmaceutical information
 - in checking drug dosages and patient identities
 - in making patient information available
- accounted for > 75% of adverse drug events
(Leape et al, 1995)



Injuries are not Accidents

- Distinct patterns
- Systems issues
- Risk groups-vulnerable populations
- Profiles of harmed patients
- Near misses precede many/all of these events
- The focus on the human actors detracts from an examination of the full range of factors that contribute to injuries



Narcotic RxWriter



Narcotic Prescriptions for Children on Discharge

 **The Johns Hopkins Hospital**
600 North Wolfe Street • Baltimore, MD 21287-6100 • (410) 955-5000

Serial No. 0339461


Age: 3
Date: 2/17/14

Valid For Controlled Substances Only

Mef-hadone 3.6mg PO Q5 (liquid)
Dispense: 3 day supply (10cc)

(Note: The entire form is crossed out with a large 'X' and an arrow points to the serial number.)

Errors on Narcotic Prescriptions (N=314)



Weight: 13 kg

Medication	Dose	Frequency	Route	Duration	PRN vs ATC	Select
Acetaminophen with Codeine Elixir	1 mg/kg/dose	q 4 hours	PO	x 10 days	PRN	Select Acetaminophen with Codeine Elixir
Acetaminophen with Codeine Tablet	1 mg/kg/dose	q 4 hours	PO	x 10 days	PRN	Select Acetaminophen with Codeine Tablet
Hydromorphone	0.05 mg/kg/dose	q 4 hours	PO	x 10 days	PRN	Select Hydromorphone
Morphine	0.3 mg/kg/dose	q 2 hours	PO	x 10 days	PRN	Select Morphine



The Johns Hopkins Hospital

Serial No.:1007977

600 North Wolfe Street * Baltimore, MD 21287-6180 * (410) 955-5000

10-26-2006

Hospital's Medical Assistance Number: 064-872-800

Name: John Doe

Age: 16 years DOB: 05/24/1990

Address: _____

Weight: 22 kg

Valid For Controlled Substances Only

Hydromorphone 1 mg/kg/dose =

Please select

q 4 hours PO

PRN (50% of ATC dose dispensed)

for 10 days

Please select

22 mg = 22 mL of Hydromorphone (1 mg per 1 mL)

24 mg = 3 Tab of Hydromorphone (8 mg per 1 tab) [ROUNDED by 9%]

Your prescription has triggered alerts.

Please note that HARD limits can overridden only by the PAIN service.

Please go back and correct your order.

Maximum Dose for Hydromorphone is 8 mg/dose (Hard Limit)

Maximum Dose for Hydromorphone is 0.2 mg/kg/dose (Hard Limit)

Maximum Dose for Hydromorphone is 0.15 mg/kg/dose (Soft Limit)

Maximum Dose for Hydromorphone is 24 mg/day (Soft Limit)

Maximum Dose for Hydromorphone is 0.9 mg/kg/day (Soft Limit)

Refill: 0 Times

May substitute:

Brand medically necessary:

Physician Signature:



The **Johns Hopkins** Hospital

600 North Wolfe Street * Baltimore, MD 21287-6180 * (410) 955-5000

Hospital's Medical Assistance Number: 064-872-800

Name: John Doe

Address: _____

Serial No.: 1007976

10-26-2006

Age: 3 years DOB: 06/26/2003

Weight: 22 kg

Valid For Controlled Substances Only

Hydromorphone Liquid 1 mg per 1 mL

Dispense: #30 mL (thirty)

Sig: Take 1 mL (1 mg Hydromorphone) PO q 4 hours prn pain for 10 days

(= 0.05 mg/kg/dose [Rounded by 9 %])

Please dispense with measuring device.

May substitute

Refill: 0 (zero) Times

Physician Signature: _____, M.D.

Physician Print Name: CHRISTOPH LEHMANN, M.D.


J.H.H. Physician ID No.: N2412

DEA No.: BL

0039 (6/03) This prescription is NOT valid as a copy. Pharmacist please check for signature indentation/imprint.



Outcome of Prescription Attempts



Medication Ordering to Reduce Errors

Prevention of Medication Errors in the Pediatric Inpatient Setting

(AAP RE9751, *Pediatrics* 1998 102:428-430)

- Confirm patient's weight
- Identify drug allergies
- Avoid abbr. (instructions, drug names, units)
- Avoid vague instructions
- Specify exact dosage strength
- Avoid terminal zero to right of decimal
- Use zero to left of decimal for numbers < 1
- Legibility



How does one change error rates?

- *Education*: Traditional approach
- *Incentives*: Nice if you can afford it
- *Automation*: Where computers come in



Errors

- Humans
 - erratic
 - err in unexpected ways
 - resourceful, inventive and flexible
 - more likely to recover from errors
- Machines
 - more dependable
 - little ability to adjust behaviors to correct to minor problems



Code Card Project

- One month survey in PICU:
 - 5% calculation errors on code cards
 - Outdated doses in infants (weight change)



Code Card Project



Johns Hopkins Children's Center CPR Card

Weight (in KG): *

Re-Enter Weight (in KG): *

Patient Last Name: *

Patient First Name:

Patient MRN:

Nurse's Name:

* mandatory information

Submit



Johns Hopkins Children's Center CPR Card Page 1/2

Patient Weight: **12 KG**

Name: **Smith, John**

Patient History #: **123-45-67**

Date: **12/07/2003**

These doses are intended for EMERGENCY / ARREST situations only

PALS DRUGS	CONCENTRATION	DOSE mL/KG	FINAL DOSE (mL)
Adenosine (0.1 mg/kg) [may double & repeat]	3mg/mL	0.033 x 12	0.4 mL ADENOSINE
Amiodarone (5 mg/kg)	50 mg/mL	0.1 x 12	1.2 mL AMIO
▶ Atropine [Bristojet] (0.02 mg/kg) *	0.1 mg/mL	0.2 x 12	2.4 mL ATRO
Calcium Chloride 10% (20 mg/kg) [PALS Dose]	100 mg/mL	0.2 x 12	2.4 mL Ca Cl
▶ Epinephrine 1:10,000 [IV / IO]	0.1 mg/mL	0.1 x 12	1.2 mL EPI
Epinephrine 1:1,000 [ALL ETT and High Dose]	1 mg/mL	0.1 x 12	1.2 mL EPI
Lidocaine (1 mg/kg) *	20 mg/mL	0.05 x 12	0.6 mL LIDO
Magnesium Sulfate (25 mg/kg)	500 mg/mL	0.05 x 12	0.6 mL MAG SULF
Naloxone TEST DOSE (0.01 mg/kg) *	0.4 mg/mL	0.025 x 12	0.3 mL NARC TEST
Naloxone (0.1 mg/kg) *	0.4 mg/mL	0.25 x 12	3 mL NARC
Sodium Bicarb (1 mEq/kg)	1 mEq/mL	1 x 12	12 mL NaHCO3
* = ETT Dose 2-3 times IV Dose	<i>After any med is administered in a peripheral line flush with 5 mL NS</i>		
DEFIBRILLATION = 25 JOULES	MAY DOUBLE AND REPEAT		
CARDIOVERSION = 6 JOULES	MAY DOUBLE AND REPEAT		

PARALYTIC DRUGS	CONCENTRATION	DOSE mL/KG	FINAL DOSE (mL)
Atropine (0.01 mg/kg) [for less than 8 years old only]	1 mg/mL	give minimum dose	0.15 mL ATRO
Rocuronium (1.2 mg/kg)	10 mg/mL	0.12 x 12	1.4 mL ROC
Succinylcholine (2 mg/kg)	20 mg/mL	0.1 x 12	1.2 mL SUCC
Vecuronium (0.2 mg/kg)	1 mg/mL	0.2 x 12	2.4 mL VEC

Hype and Reality

- Institute of Medicine reports
 - POE one of 14 med-safety recommendations, not centerpiece
 - *To Err Is Human*, p. 183, 191-92
 - Greater emphasis on simple, proven fixes
 - Unit dosing, pharmaceutical software, standard solutions
- Leapfrog: altruism and self-interest
 - Not just Fortune 500 employers
 - Every major insurer (formulary control, physician-specific drug usage)
 - Every major clinical IT vendor



POE meets clinical reality

- Pre-POE written orders expressed *intent*, which a domain expert (pharmacist, RN, rad tech, etc.) translated into action
- POE removes the translator
 - Precision vs. accuracy
 - End-user data entry requires either simple interface or expert user; POE has complex interface, part-time users
 - Order nuances (schedule, stop date, linking) often opaque even to expert users
 - POE requires unfamiliar granularity in each order (schedule, carrier, formulation, etc.)
 - POE picklists make visible entire formulary, including unfamiliar options (20 forms of insulin, 10 of morphine, etc.) that users sometimes order by mistake
 - Ancillaries, previously expert fixers/mediators, now simply reject orders and tell docs to re-enter → delay in care delivery



Standard alert signal & noise

- Drug-drug interaction
 - 15% of drug orders triggered alerts
 - House staff overrode 97.4% of alerts
 - 2.6% that resulted in order changes,
 - two-thirds of substitutions inappropriate or dangerous
 - » Heparin + coumadin, clopidogrel + aspirin, spironolactone + potassium
 - Ambiguous messages such as “GENERALLY AVOID” or “CONTRAINDICATED”
 - Alert invisible to pharmacists
 - Did not distinguish med route (ophthalmic beta blockers)



The Paper Albatross

- Creates more paper
- Paper is recycled faster
- Orders have to be printed to provide a hard copy back up
- 24 hour summary printout
- One screen order set may translate into 13 pages of printed orders



Interface Problems

- Juxtaposition Error
 - “Something is too close to something else”
 - “Clicked the wrong thing”
- Wrong Patient
 - Not all interfaces make the patient context clear
- Wrong Time



Cost

- High Profile failure (Cedars Sinai)
- Purchase price low compared to implementation costs (1:10)

- Brigham and Women's Hospital
 - cumulative net savings of \$16.7 million
 - net operating budget savings of \$9.5 million
 - break-even after 5-8 years)

Kaushal R, Jha AK, Franz C, Glaser J, Shetty KD, Jaggi T, Middleton B, Kuperman GJ, Khorasani R, Tanasijevic M, Bates DW. Return on Investment for a Computerized Physician Order Entry System. J Am Med Inform Assoc. 2006 Feb 24;



THANK YOU



clehmann@jhmi.edu





Year 1: Using Risk Models to Identify and Prioritize Outpatient High-Alert Medications

Years 2-4: Risk-Informed Interventions in Community Pharmacy: Implementation and Evaluation

Donna Horn, RPh, DPh
Judy Smetzer, RN, BSN, FISMP

These studies are supported by grant numbers 1P20HS017107 and R18HSO17910 from the Agency For Healthcare Research and Quality

I do not have any relevant financial relationships with any commercial interests to disclose.

Year 1: Using Risk Models to Identify and Prioritize Outpatient High-Alert Medications

Aims

- Develop risk models for four high-alert medications
- Identify error pathways
- Identify approaches for reducing the risk of harm

Methods

- Mapped out the dispensing processes
- Focus group provided input into the construction of the risk models for each high-alert medication
- Quantified the risk of failures within risk models
- Determined the impact of error-reduction strategies



Details: Point-of-Sale Errors

- Initiating errors
 - Bagging error: 0.4/1,000
 - Retrieval error: 3/1,000
- PADE: 1.22/1,000 (64% capture)
- Opening bag at point of sale
 - 56% reduction in PADE (0.534/1,000)
- Increase compliance with identification from 50% to 80%
 - 34% reduction in PADE (0.804/1,000)
- Increase patient counseling from 30% to 80%
 - 27% reduction in PADE
- Interventions together: 86% reduction



Details: Selecting the Wrong Dose

- Wrong dose of warfarin
 - Initiating error 1/10 prescriptions
 - PADE: 9.25/10 million prescriptions (99.9% capture)
 - Eliminate barcode scanning
 - 95,340% **increase** in risk (9/10,000)
 - Use cheat sheet 30% of time
 - 265,011% **increase** in risk (2/10,000)
 - Increase patient counseling from 30% to 80%
 - 67% reduction in risk (3/10 million)
 - Increase automated dispensing from 20% to 50%
 - 35% reduction in risk (5/10 million)
 - Two interventions together: 78% reduction in risk



Details: Prescribing Errors

- Wrong dose of fentanyl or inappropriate use of drug
 - Initiating error 1/1,000 prescriptions
 - PADE: 7.30/10,000 prescriptions (27.0% capture)
 - Opioid history at drop off (50% patients, 40% capture rate)
 - 40% decrease in risk (0.439/1,000)
 - Increase patient counseling from 10% to 80%
 - 64% decrease in risk (0.263/1,000)
 - Two interventions together
 - 78% decrease in risk



Discussion and Conclusions

- Prescribing errors
 - Designed to capture straightforward mistakes
 - Poorly designed to capture errors associated with inappropriate drugs or doses due to patient factors
 - More frequent and effective counseling
 - Reduce PADEs by 64%
- Dispensing errors
 - Vulnerable to data entry errors, wrong patient errors
 - Second verification process reduced risk by 87%
 - Opening bag during customer sale reduced risk by 56%
 - Reliable for detecting drug/dose selection errors due to bar-coding, automated dispensing, pill images



Years 2-4: Risk-Informed Interventions in Community Pharmacy: Implementation

- Intervention 1
 - Scripted mandatory patient counseling
 - Warfarin and low-molecular weight heparin
 - Fentanyl patches
 - Methotrexate
 - Insulin analogs
 - Hydrocodone and oxycodone (with acetaminophen)
- Intervention 2
 - Readiness assessment for bar-coding technology
- Intervention 3
 - Risk assessment/intervention scorecard using risk models from first study: HAMERS tool



Intervention 1: Patient Counseling

- Pre-intervention observation in pharmacies
 - 50 observations completed
 - 4 states
 - 2 with mandatory counseling
 - 2 with mandatory offer to counsel
 - Preliminary findings
 - No counseling in states with offer to counsel
 - Counseling for OTCs more common than for prescription drugs
 - More frequent counseling in states with mandatory counseling
 - Differences between state enforcement of counseling
 - Not covering information linked to PADEs



Intervention 1: Patient Counseling

- Implementation Tool Kit
 - Scripted counseling materials, checklists, health questions
 - Consumer handouts about targeted drugs
 - Specifically targets known causes of PADEs





Read this important information before taking:

Warfarin

Brought to you by the Institute for Safe Medication Practices

[Extra care is needed because warfarin is considered a high-alert medicine.]

Just a handful of medicines are considered **high-alert medicines**. These medicines are necessary to keep people healthy.

They have been proven to be safe and effective when taken properly. But these medicines can cause serious **injury** if a mistake happens while taking them.

This means that it is vitally important for you to know about this medicine and take it exactly as intend.



When taking your medicine

- 1 Take exactly as directed. Take your medicine at the same time each day, preferably in the evening. Do not take extra doses or skip doses.



When the doctor changes your dose

- 2 Keep a record of telephone calls. When your doctor calls to change your dose: write down the dose and any other instructions; read the dose and instructions back to the doctor to make sure you understand them; and date the instructions so they won't be mixed up with older instructions.



- 3 Know your dose. Always tell your doctor the strength of warfarin tablets that you have on hand. Then ask him how much warfarin to take, and how many tablets in that strength to take to equal the dose. If you are running low on tablets, ask for a new prescription.

- 4 Keep instructions nearby. Keep the dated instructions near the medicine, and read them every time before taking your warfarin.



- 5 Restart your medicine. If your doctor told you to stop taking warfarin until your next blood test, call him if you don't hear from him within 24 hours of the test to find out your new dose.



To avoid serious side effects

- 6 Keep to your regular habits. Keep your eating habits and exercise regular. Know the foods high in vitamin K to avoid or eat consistently (see back). Tell your doctor if there has been a recent change in your level of exercise, smoking, or diet.

- 7 Take precautions. Because serious bleeding can occur, take precautions such as avoiding fall risks and sharp objects, and using an electric razor.

- 8 Get periodic blood tests. Keep all appointments for blood tests (called INR). Call your doctor for your test results if you are not contacted within 1 day of the test.

When you should call your doctor

- 9 Signs of bleeding or clot. Call your doctor immediately if you experience any signs of bleeding or clot formation, which are listed on the back.

- 10 New medicines. Do not start or stop any prescription or non-prescription medicines, herbs, and vitamins, without telling your doctor. Non-prescription medicines to avoid can be found on the back.



Watch for Signs of Bleeding or Clot!

Serious bleeding can occur even if you take warfarin exactly as prescribed. Also, you can still get a blood clot while taking warfarin. Report any signs of bleeding and clots—listed on the back—to your doctor immediately.

Warfarin tablets may come in different shapes. But each strength comes in just one color. Make sure the color of your tablets matches the strength your doctor prescribed.



For more information to help keep you safe, visit: www.consumersafety.org.

Warfarin

Too little, too much!

Too little warfarin can lead to a blood clot. Too much warfarin can lead to bleeding.

Report these signs to your doctor immediately!



Signs of bleeding

- Unusual pain, swelling, discomfort
- Unusual or easy bruising
- Pink or brown urine
- Prolonged bleeding from cuts or gums
- Persistent frequent nosebleeds that don't stop within 7 minutes
- Unusually heavy/long menstrual flow
- Coughing up blood

- Vomit that is bloody or looks like coffee grounds
- Severe dizziness, weakness, headache, fainting, unusual or persistent tiredness
- Bloody or black stools
- Chest pain, shortness of breath, difficulty swallowing
- Pain in joints or back



Signs of a clot

- Lung: chest pain, fast heart rate, coughing, shortness of breath, fever
- Arm or leg: sudden leg, arm, or back pain, swelling, redness and warmth, tenderness
- Brain: headache, vision changes, seizure, slurred speech, weakness on one side of body, loss of balance
- Heart: chest pain, shortness of breath, sweating, nausea and vomiting
- Abdomen: abdominal pain, vomiting, diarrhea



Foods high in vitamin K

Avoid

- Cranberries/cranberry juice

Avoid or eat in consistent amounts

- Beef or pork liver
- Green tea
- Broccoli and Brussels sprouts
- Chick peas
- Green leafy vegetables: spinach, kale, green tumpts
- Parsley
- Many oils



Topics	Fast Facts
Generic name	warfarin (pronounced WAR far in) (generic medicine available)
Common brand names	Coumadin and Jantoven
Uses	Prevent and treat blood clots in certain conditions that increase the risk of clots: surgery, heart attack, heart rhythm problem, heart valve replacement, immobility after an accident Prevent transient ischemic attacks (brief episodes of inadequate oxygen to the brain)
Usual dose limits	2 mg to 10 mg daily for adult patients Doses are adjusted based on INR blood test results
What to do if you miss a dose	If it is still the same day, take the dose as soon as you remember it If it is the next day, skip the missed dose and take your normal dose Do not double the dose to catch up Contact your doctor if you miss two or more doses in a row
Special instructions and precautions	Take exactly as prescribed, the same time each day in the evening Avoid alcohol, keep eating habits and exercise regular You will have a tendency to bleed easily, so use a soft toothbrush, waxed dental floss, electric razor, avoid sharp objects and falling risks Do not start or stop any medicine, including over-the-counter medicines, herbs, and vitamins, without letting your doctor or pharmacist know
Safety during pregnancy/breastfeeding	Do not take when pregnant, may cause fetal bleeding or abnormalities May take while breastfeeding, but let the infant's doctor know for proper monitoring
Tell your doctor if you have:	Diseases: bleeding disorders, kidney, liver, thyroid disease, severe high blood pressure, diabetes Conditions: surgery, history of falls or if you are at risk for falls, open wound
Storage and disposal	Store at room temperature, protect from light and moisture (do not store in bathroom) Dispose tablets securely in the trash, do not flush down the toilet
Side effects to report to your doctor immediately	Signs of bleeding or clot (see above), skin irritation, painful red-purple patches on skin (toe, breast, abdomen), unusual fever, unhealed wounds, yellowing eyes or skin
Other conditions to report to your doctor	Accidents or falls, new or stopped medicines (including over-the-counter, herbs, and vitamins), changes in smoking or eating habits, infection, fever, use of antibiotics
Over-the-counter medicines/herbals/vitamins that should not be taken with warfarin	Aspirin, non-steroidal anti-inflammatory drugs (ibuprofen [Achi, Motrin], naproxen [Aleve]), most herbals (particularly cranberry, fenugreek, garlic, ginkgo biloba, glucosamine, ginseng [American], ginger, goldenseal, coenzyme Q, St. John's wort, alfalfa, anise, bilberry), cimetidine (Tagamet), vitamin A, vitamin E
Prescription medicines that should not be taken with warfarin	Many prescription medicines interact with warfarin Tell your doctor about all the medicines you take
Special tests your doctor may prescribe	You must have blood tests (called "INR") checked regularly Your doctor will determine the right INR level (usually between 2.5 to 4) for you

This information does not replace the need to read the drug information leaflet provided with your prescription and follow your doctor's instructions.

This project was supported by grant number R18HS017910 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not represent the official views of the Agency for Healthcare Research and Quality.

Intervention 1: Patient Counseling

Measures

- Post-implementation observation
 - Prescribing/dispensing/self-administration errors
 - Barriers/facilitators to counseling
 - Quality of counseling sessions
- Self-administered surveys to patients
 - Perception of counseling encounter/value of handouts
 - Increase understanding? New information? Change behavior?
 - Require treatment for a PADE?
- Self-administered surveys to pharmacists
 - Perceived value and impact of counseling



Intervention 2: Bar-coding Readiness Assessment

- 46-50% of community pharmacies in the US **do not** use barcode technology for product verification
- 100 pharmacies participating in the study
- Survey to determine why non-users are still non-users
- Phase 1
 - 5 pharmacies pilot testing the tool
 - 100 pharmacies will complete the assessment and submit findings
 - Pharmacies will complete survey to measure perceived value
- Phase 2
 - Pharmacies from Phase 1 that have since implemented bar-coding will complete survey to measure actual value



Table of Contents

5 COMMUNITY PHARMACIES

Advisory Panel	2
Executive Summary	3
Instructions for Conducting the Readiness Assessment	4
Important Details about the Readiness Assessment Tool.....	4
Directions for Using the Readiness Assessment Tool	4
Directions for Entering Data and Generating Reports.....	6
Legal Protection of Readiness Assessment Data Submitted to ISMP.....	7
Readiness Assessment for Pharmacy Leadership/Owner	8
Demographics.....	8
Readiness Assessment Tool.....	9
Readiness Assessment for Pharmacy Staff	15
Demographics.....	15
Readiness Assessment Tool.....	16
Appendix A—Putting Bar-Coding Technology into Context	20
Uses and Benefits of Bar-coding Technology in Community Pharmacies.....	20
Impact of Barcode Product Verification Systems on Dispensing Errors	21
Incidence of Bar-Coding Technology in Community Pharmacies.....	21
Factors that Impact the Decision to	
Implement a Barcode Product Verification System	22
Challenges Implementing Barcode Product Verification Systems.....	23
Selecting the Right Barcode Product Verification System	24
Costs Associated with Barcode Product Verification Systems	24
Conclusions	24
Appendix B—Vendor Selection	25
Elements to Consider During Vendor Selection.....	25
Appendix C—Costs	29
Direct Costs Associated with Barcode Verification Systems	29
References	30

*Photo on front cover courtesy of Kirby Lester, LLC.

2011 © Institute for Safe Medication Practices

ASSESSING BARCODE VERIFICATION SYSTEM READINESS in COMMUNITY PHARMACIES

FROM THE INSTITUTE FOR SAFE MEDICATION PRACTICES



Educating the healthcare community about safe medication practices

This project was supported by grant number R18HS017910 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality.

- ① No activity
- ② Possible Implementation
- ③ Partially Implemented
- ④ Fully Implemented *Some*
- ⑤ Fully Implemented *All*

Prerequisite:
Item should be in place before implementing bar-coding

Facilitator:
Item not required but would make it easier to implement bar-coding

Item #	Prerequisite/ Facilitator	Element	①	②	③	④	⑤	NA
Technology Environment								
1	F	The pharmacy has successful experience with integrating/interfacing information system technologies.						
2	F	Barcode technology is available and already used for various functions in the pharmacy (e.g., point of sale, reordering stock)						
3	F	A network to support information transfer via radio frequency is available in the pharmacy.						
4	P	Information systems are protected with security and access control systems.						
5	P	An information system back-up process has been prepared in case of a technology failure.						
6	P	Recovery and back-up plans associated with technology failures are regularly tested in the pharmacy or pharmacies.						
7	P	Resource allocation plans for a barcode product verification system have factored in the costs associated with hardware and software requirements (including interface costs), and staffing resources needed to maintain the system.						
Physical Environment								
8	P	Consideration has been given to where to place computer terminals, docking stations, battery chargers, and other equipment associated with a barcode verification system in a manner that best supports the natural workflow of the dispensing process.						
9	P	There is adequate space in the production section of the pharmacy for computer terminals and other hardware associated with a barcode verification system.						
10	P	There is adequate space in the prescription verification section of the pharmacy for computer terminals and other hardware associated with a barcode verification system.						
11	P	There are sufficient electrical outlets in the pharmacy for charging and operating the equipment associated with a barcode verification system.						
12	P	Resource allocation plans for a barcode product verification system have factored in costs associated with changes needed in the physical environment.						
Workflow								
13	P	The processes associated with medication dispensing have been thoroughly examined through flowcharting or process mapping to promote detailed understanding of staff needs and the current workflow.						

continued on next page

Intervention 3: HAMERS


(High-Alert Medication Error Risk Scorecard)

- Risk models translated into practical assessment tool and scorecard
- Tool Kit will include:
 - HAMERS tool (webpage download)
 - Scorecard with qualitative (distribution of risk) and quantitative (PADE rates) information
 - Tool calculations driven by reports from original risk models



Intervention 3: HAMERS

- 3 principal elements
 - AND gates
 - OR gates
 - basic events
- Includes the effects of:
 - Capture opportunities
 - Human errors
 - At-risk behaviors and procedural deviations
 - Mechanical/technology failures
- Modeling team estimates rates of failure based on human factors



Human Error Probabilities

Probability estimates to quantify risk

Unfamiliar task performed at speed/no idea of consequences	5:10
Task involving high stress levels	3:10
Complex task requiring high comprehension and skill	15:100
Select ambiguously labeled control/package	5:100
Failure to perform a check correctly	5:100
Error in routine operation when care required	1:100
Well designed, familiar task under ideal conditions	4:10,000
Human performance limit	1:10,000



Intervention 3: HAMERS

Inputs

- Set-up questions
 - System attributes: Require data entry verification for pharmacists?
 - Availability: Use bar-coding technology? Specific computer alerts?
 - Prescription volumes?
- Exposure rates
 - Frequency of counseling patients?
- Capture opportunities
 - What percent of errors will not be caught during this step?
- At-risk behaviors
 - Frequency of choosing not to ask a customer for a second identifier?
- Human errors
 - Frequency of forgetting to read back an oral prescription? (preset)

Intervention 3: HAMERS

Outputs

- Scorecard that quantifies the risk of specific PADEs
- Bar graph that shows distribution of risk
 - Which tasks/elements contribute most to the PADE?
- Menu of interventions to reduce risk
 - Pharmacy makes changes to inputs based on the planned interventions
 - Pharmacy receives a revised scorecard that quantifies improvements based on planned interventions
 - If (intervention) is implemented, then risk that the PADE will reach the patient is ___%.
 - If risk factor is (increased/decreased) by __%, then risk that the PADE will reach the customer is ___%.



High-Alert Medication Error Reduction Scorecard (HAMERS)

Drug Selection

Instructions

You have selected the tool associated with **wrong dose prescribing errors**. Now you must specify which **high-alert medication(s)** you want to evaluate, and how often you fill prescriptions for these medications. While this tool can be used to evaluate **wrong dose prescribing errors** with any drug, focusing on high-alert medications helps to reduce the risk of errors that can cause the greatest harm to patients.

OK

Question 1a

Please list the name(s) of the medication(s) or class of medications involved in the **wrong dose prescribing errors** you want to evaluate.

Answer - Medications List:

Question 1b

Please provide the number of prescriptions (new prescriptions and **refills** combined) filled annually for the medications involved in these errors.

Include generic brands and all strengths if applicable. Add all generics, brands, and strengths together.

Answer - Number of prescriptions filled annually:

Denominator

BACK

SAVE

FAQ

High-Alert Medication Error Reduction Scorecard (HAMERS)

Data Entry of Prescription (Drug Type and Error)

Instructions

The next set of questions are associated with the process of entering the prescription into the pharmacy computer. The questions will explore how often pharmacists and **pharmacy associates** enter prescriptions for these medications, and how many prescriptions are for **refills** or for **new patients** (patients new to the pharmacy or new to the drug therapy). You will also be asked to estimate how often the **wrong dose prescribing errors** are missed during **data entry** given specified conditions. This set of questions apply only to the **data entry** process. The **data entry verification** process and **drug utilization review** process are addressed in a later section.

OK

Question 7

What percent of prescriptions for these medications are entered into the pharmacy computer by a **pharmacy associate** (e.g., technician, pharmacy student, pharmacy resident)? (E57 and E59)

Please be sure to consider daytime, nighttime, and weekend/holiday staffing when averaging the percents.

Answer: 0%, <1%, 1%, 5%, then 5% increments

EXPOSURE RATE

BACK

SAVE

FAQ

Question 9

A pharmacist is entering a prescription into the profile of an **existing patient** who has previously taken the same drug or another drug within the same class. On average, what percent of the **wrong dose prescribing errors** will be missed by a pharmacist during data entry (when there are no computer dose alerts)? (E68)

Note: This does not include response to computer alerts; alerts are factored in during the pharmacists' **drug utilization review** (DUR). Just estimate how often the pharmacist would miss the prescribing error during the data entry process without the help of a computer alert.

Answer: <1%, 1%, 5%, then 5% increments

Missed Capture Opportunity

Question 25

What percent of the time does a pharmacist ignore the **duplicate therapy** alert for the medications in question or fail to give the alert his/her full attention? (E63)


Answer: 10%, 15%, then in 5% increments

At-risk Behavior

High-Alert Medication Error Reduction Scorecard (HAMERS)

Scorecard Risk Report

Rank ordering of Risk Contributors



Print

SAVE

Thank You!

Donna Horn: dhorn@ismp.org

Judy Smetzer: jsmetzer@ismp.org



Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

Questions & Answers

Our Panel:

Donna Horn, R.Ph., D.Ph., director of patient safety at the Institute for Safe Medical Practices (ISMP)

Andrea M. Wessell, PharmD., B.C.P.S., C.D.E., associate professor at the Medical University of South Carolina and PPRNet (Practice Partner Research Network) investigator

Christoph “Chris” U. Lehmann, M.D., F.A.A.P., associate professor of pediatrics and a board-certified neonatologist in the Eudowood Neonatal Pulmonary Division at the Johns Hopkins University School of Medicine

Judy Smetzer, R.N., B.S.N., vice president at the Institute for Safe Medication Practices (ISMP)

Coming Soon!

Our next event

A webinar examining health information technology and patient centered care

Stay tuned for exact date, time and registration information

**AHRQ National Resource Center
for Health Information Technology**



AHRQ

Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

Thank You for Attending

This event was brought to you by the
AHRQ National Resource Center for Health IT

The AHRQ National Resource Center for Health IT promotes best practices in the adoption and implementation of health IT through a robust online knowledge library, Web conferences, toolkits, as well as AHRQ-funded research outcomes.

A recording of this Web conference will be available on the AHRQ National Resource Center Web site within two weeks.

<http://healthit.ahrq.gov>

**AHRQ National Resource Center
for Health Information Technology**



AHRQ

Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

Median Summary Performance in Medication Safety Measures Over Time

	<i>Jul 08</i>	<i>Oct 08</i>	<i>Jan 09</i>	<i>Apr 09</i>	<i>Jul 09</i>	<i>Oct 09</i>	<i>Jan 10</i>	<i>Apr 10</i>	<i>Jul 10</i>
Avoiding Potential Drug-Drug Interactions	98.8%	98.5%	98.5%	98.4%	98.7%	98.8%	98.4%	98.6%	98.5%
Avoiding Potentially Inappropriate Dosing	88.0%	89.7%	90.4%	92.5%	93.6%	92.3%	89.8%	91.8%	90.4%
Avoiding Potential Drug-Disease Interactions	87.2%	87.1%	88.7%	89.3%	88.3%	88.2%	88.0%	88.9%	89.4%
Avoiding Potentially Inappropriate Therapy	69.9%	70.8%	68.7%	76.3%	79.6%	79.3%	80.6%	81.1%	82.6%
Monitoring/ Preventing Potential Adverse Drug Events	74.2%	75.5%	77.9%	78.6%	79.2%	79.2%	80.1%	80.3%	79.8%

*P= 0.05

1=No activity
 2=Possible Implementation
 3=Partially Implemented
 4=Fully Implemented (some)
 5=Fully Implemented (all)

Prerequisite: Item should be in place before implementing bar coding

Facilitator: Item not required but would make it easier to implement bar coding

Item #	Prerequisite/ Facilitator	Element	1	2	3	4	5	N/A
Technology Environment								
1	F	The pharmacy has successful experience with integrating/interfacing information system technologies.						
2	F	Barcode technology is available and already used for various functions in the pharmacy (e.g. point of sale, reordering stock)						
3	F	A network to support information transfer via radio frequency is available in the pharmacy.						
4	P	Information systems are protected with security and access control systems.						
5	P	An information system back up process has been prepared in case of a technology failure.						
6	P	Recovery and back up plans associated with technology failures are regularly tested in the pharmacy or pharmacies.						
7	P	Resource allocation plans for a barcode product verification system have factored in the costs associated with hardware and software requirements (including interface costs), and staffing resources needed to maintain the system.						
Physical Environment								
8	P	Consideration has been given to where to place computer terminals, docking stations, battery chargers, and other equipment associated with a barcode verification system in a manner that best supports the natural workflow of the dispensing process.						
9	P	There is adequate space in the production section of the pharmacy for computer terminals and other hardware associated with a barcode verification system.						
10	P	There is adequate space in the prescription verification section of the pharmacy for computer terminals and other hardware associated with a barcode verification system.						
11	P	There are sufficient electrical outlets in the pharmacy for charging and operating the equipment associated with a barcode verification system.						
12	P	Resource allocation plans for a barcode product verification system have factored in costs associated with charges needed in the physical environment.						
Workflow								
13	P	The processes associated with medication dispensing have been thoroughly examined through flowcharting or process mapping to promote detailed understanding of staff needs and the current workflow.						